

Alpha-1 Proteinase Inhibitors

Glassia, Prolastin-C, Zemaira, Aralast NP



Treatment Location: _____

PROVIDERS: Please include the following to expedite the order:

Patient Demographics, Most Recent Office Visit Note, Insurance Information, Labs or testing that indicates severe Alpha1-PI deficiency

PATIENT INFORMATION

Referral Status: New Referral Updated Order Order Renewal

Date: _____ Patient Name: _____ Patient Phone: _____ DOB: _____

ICD-10 code (required): E88.01 ICD Description: _____

Allergies: _____ Weight (lbs/kg): _____ Height: _____

Patient Status: New to Therapy Continuing Therapy Last Treatment Date: _____ Next Due Date: _____

PROVIDER INFORMATION

Referral Coordinator Name: _____ Referral Coordinator Email: _____

Ordering Provider: _____ Provider NPI: _____

Referring Practice Name: _____ Phone: _____ Fax: _____

Practice Address: _____ City: _____ State: _____ Zip: _____

NURSING

Center will use Hypersensitivity protocol established by Infusion for Health and PI

PRE-MEDICATION ORDERS

Pre-medications not usually indicated.

Diphenhydramine 25mg / 50mg PO / IV
 Acetaminophen 325mg / 500mg / 650mg PO
 Other: _____
Dose: _____ Route: _____ Frequency: _____

SPECIAL INSTRUCTIONS:

LABORATORY ORDERS

CBC at each dose every _____
 CMP at each dose every _____
 Other: _____ Frequency: _____

Please check this box if you DO NOT authorize Infusion for Health to order and draw labs indicated for clinical clearance and/or insurance authorization prior to treatment.

THERAPY ADMINISTRATION

Alpha-1 Proteinase Inhibitor Intravenous Infusion
 Preferred Brand: _____
 Administer 60mg/kg once weekly
Infusion for Health will round the dose to the nearest vial if it is within +/- 10% of calculated dose, otherwise we will give exact dose.
 Refills: Zero / for 12 months / _____
(if not indicated order will expire one year from date signed)

To ensure that a brand name product is dispensed, the prescriber must handwrite "Brand Medically Necessary" on the prescription form. If not indicated, I4H is authorized to administer a generic or biosimilar.

Provider Name (Print) _____ Provider Signature _____ Date _____

Please check this box if you DO NOT authorize Infusion for Health to complete a Peer to Peer on behalf of the prescribing provider for an insurance company that denies authorization for treatment.